Insider Activity of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) belonging to the Medical sector which declined -2.31% and closed its last trading session at $7.18.

The company reported its last EPS on 6/30/2016 and is expected to report its next EPS on 12/12/2016. Currently, the stock has a 1 Year Price Target of $10.75.

The consensus recommendation, according to Zacks Investment research, is 1.4. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 1.4 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.67 and 1.67 respectively.

Arrowhead Pharmaceuticals, Inc. on 6/30/2016 reported its EPS as $-0.32 with the analysts projecting the EPS of the stock as $-0.37. The company beat the analyst EPS Estimate with the difference of $0.05. This shows a surprise factor of 13.5%.

Many analysts have provided their estimated foresights on Arrowhead Pharmaceuticals, Inc. Earnings, with 5 analysts believing the company would generate an Average Estimate of $-0.32. Whereas they predicted High and Low Earnings Estimate as $-0.31 and $-0.37 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.41.

For the Current Quarter, the growth estimate for Arrowhead Pharmaceuticals, Inc. is 22%, while for the Next Quarter the stock growth estimate is -6.3%. In the past 5 years, the stock showed growth of 0% per annum. While for the next 5 years, the growth estimate is 7.33%.

The Company got Initiated by Cantor Fitzgerald on 18-Aug-16 to Buy.

Insider Trades for Arrowhead Pharmaceuticals, Inc. show that the latest trade was made on 22 Aug 2016 where Myszkowski (Kenneth A), the Chief Financial Officer completed a transaction type “Sell” in which 6900 shares were traded at a price of $8.

 

6 analysts projected Price Targets for Arrowhead Pharmaceuticals, Inc. The analysts believe that the company stock price could grow as high as $15. The Low Price target projection by analysts is $5.5 and the Mean Price Target is $10.75.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has the market capitalization of $433.24 Million. The company rocked its 52-Week High of $8.22 on Aug 24, 2016 and touched its 52-Week Low of $3.07 on Feb 11, 2016. The stock has Return on Assets (ROA) of -79.5 percent. Return on Equity (ROE) stands at -99.8% and Return on Investment (ROI) of -86.5 percent.

The stock is currently showing YTD performance of 16.75 Percent. The company has Beta Value of 2.35 and ATR value of 0.43. The Weekly and Monthly Volatility stands at 6.55% and 5.23%.

Company profile:

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company’s proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.